中文摘要：

目的分析乳腺浸润性导管癌组织中免疫分子B7-H3的表达及其与患者的临床病例参数及肿瘤间质中CD3＋、CD4＋T淋巴细胞浸润程度的相关性。方法收集2009年1月至2009年12月在苏州市立医院北区行手术切除术的乳腺浸润性导管癌患者组织标本88例,免疫组织化学的方法检测乳腺浸润性导管癌组织中免疫分子B7-H3及CD3、CD8指标的表达。结果乳腺浸润性导管癌组织中有66例免疫分子B7-H3高表达,该分子的表达与患者的年龄、性别、淋巴结的转移情况、肿瘤的大小、肿瘤分期无相关性（P〉0.05）,但与患者HER2基因表达相关（P〈0.05）。且该分子在乳癌中的表达水平与浸润的T淋巴细胞呈正相关。结论免疫分子B7-H3的表达在乳腺浸润性导管癌组织的诊断和预后判断中具有潜在的临床应用价值。

英文摘要：

This study designed to study the expression of B7-H3 in invasive ductal carcinoma of breast and its correction with pathological parameters, prognosis and the intensity of tumor infiltrating CD3＋, CD8＋T lymphocytes.Total of 88 samples of invasive ductal breast cancer were collected from the Forth Hospital of Suzhou between Jan.and Dec. 2009, and the expression levels of B7-H3, CD3, and CD8 were detected by immunohistochemical assay.Data showed that B7-H3 was expressed in 66 samples of invasive ductal breast cancer, which was correlated the Her2 gene and the intensity of tumor infiltrating CD3＋, CD8＋T lymphocytes, but not related with the patient＇s age,sex, lymph node metastasis, tumor size and tumor status（P〉0.05）. In conclusion, B7-H3 expression detection in breast cancer tissue is beneficial to the judgment of the prognosis of breast cancer and the treatment strategy selection.